Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
Edoxaban, a once-daily, direct-acting oral anticoagulant, is approved to prevent stroke or systemic embolism in non-valvular atrial fibrillation (NVAF) and treat venous thromboembolism. The clinical benefit of edoxaban for stroke prevention in Asian patients with NVAF has been demonstrated in clinic...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioexcel Publishing
2023
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/107426/1/107426.pdf |
| _version_ | 1817927459438329856 |
|---|---|
| author | Bimbo Diaz, Alejandro Chow, Jeremy Fan, Kee Hoo Kok, Wei Koh Chin, Gary Keong Lee Wee, Siong Teo Venketasubramanian, Narayanaswamy Chun, Chieh Wang Mehta, Radhika |
| author_facet | Bimbo Diaz, Alejandro Chow, Jeremy Fan, Kee Hoo Kok, Wei Koh Chin, Gary Keong Lee Wee, Siong Teo Venketasubramanian, Narayanaswamy Chun, Chieh Wang Mehta, Radhika |
| author_sort | Bimbo Diaz, Alejandro |
| collection | UPM |
| description | Edoxaban, a once-daily, direct-acting oral anticoagulant, is approved to prevent stroke or systemic embolism in non-valvular atrial fibrillation (NVAF) and treat venous thromboembolism. The clinical benefit of edoxaban for stroke prevention in Asian patients with NVAF has been demonstrated in clinical and real-world studies. We share early clinical experiences with once-daily edoxaban and discuss its evidence-based use in patients with NVAF in Southeast Asia through several cases of patients at high risk, including frail patients, elderly patients with multiple comorbidities and patients with increased bleeding risk. These cases demonstrate the effectiveness and safety of once-daily edoxaban in patients with NVAF in Southeast Asia. |
| first_indexed | 2024-12-09T02:18:47Z |
| format | Article |
| id | upm.eprints-107426 |
| institution | Universiti Putra Malaysia |
| language | English |
| last_indexed | 2024-12-09T02:18:47Z |
| publishDate | 2023 |
| publisher | Bioexcel Publishing |
| record_format | dspace |
| spelling | upm.eprints-1074262024-11-04T02:35:08Z http://psasir.upm.edu.my/id/eprint/107426/ Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region Bimbo Diaz, Alejandro Chow, Jeremy Fan, Kee Hoo Kok, Wei Koh Chin, Gary Keong Lee Wee, Siong Teo Venketasubramanian, Narayanaswamy Chun, Chieh Wang Mehta, Radhika Edoxaban, a once-daily, direct-acting oral anticoagulant, is approved to prevent stroke or systemic embolism in non-valvular atrial fibrillation (NVAF) and treat venous thromboembolism. The clinical benefit of edoxaban for stroke prevention in Asian patients with NVAF has been demonstrated in clinical and real-world studies. We share early clinical experiences with once-daily edoxaban and discuss its evidence-based use in patients with NVAF in Southeast Asia through several cases of patients at high risk, including frail patients, elderly patients with multiple comorbidities and patients with increased bleeding risk. These cases demonstrate the effectiveness and safety of once-daily edoxaban in patients with NVAF in Southeast Asia. Bioexcel Publishing 2023-09-08 Article PeerReviewed text en cc_by_nc_nd_4 http://psasir.upm.edu.my/id/eprint/107426/1/107426.pdf Bimbo Diaz, Alejandro and Chow, Jeremy and Fan, Kee Hoo and Kok, Wei Koh and Chin, Gary Keong Lee and Wee, Siong Teo and Venketasubramanian, Narayanaswamy and Chun, Chieh Wang and Mehta, Radhika (2023) Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region. Drugs in Context, 12 (3). pp. 1-15. ISSN 1745-1981; eISSN: 1740-4398 https://www.drugsincontext.com/early-experiences-with-edoxaban-for-stroke-prevention-in-atrial-fibrillation-in-the-southeast-asia-region/ 10.7573/dic.2023-3-3 |
| spellingShingle | Bimbo Diaz, Alejandro Chow, Jeremy Fan, Kee Hoo Kok, Wei Koh Chin, Gary Keong Lee Wee, Siong Teo Venketasubramanian, Narayanaswamy Chun, Chieh Wang Mehta, Radhika Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region |
| title | Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region |
| title_full | Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region |
| title_fullStr | Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region |
| title_full_unstemmed | Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region |
| title_short | Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region |
| title_sort | early experiences with edoxaban for stroke prevention in atrial fibrillation in the southeast asia region |
| url | http://psasir.upm.edu.my/id/eprint/107426/1/107426.pdf |
| work_keys_str_mv | AT bimbodiazalejandro earlyexperienceswithedoxabanforstrokepreventioninatrialfibrillationinthesoutheastasiaregion AT chowjeremy earlyexperienceswithedoxabanforstrokepreventioninatrialfibrillationinthesoutheastasiaregion AT fankeehoo earlyexperienceswithedoxabanforstrokepreventioninatrialfibrillationinthesoutheastasiaregion AT kokweikoh earlyexperienceswithedoxabanforstrokepreventioninatrialfibrillationinthesoutheastasiaregion AT chingarykeonglee earlyexperienceswithedoxabanforstrokepreventioninatrialfibrillationinthesoutheastasiaregion AT weesiongteo earlyexperienceswithedoxabanforstrokepreventioninatrialfibrillationinthesoutheastasiaregion AT venketasubramaniannarayanaswamy earlyexperienceswithedoxabanforstrokepreventioninatrialfibrillationinthesoutheastasiaregion AT chunchiehwang earlyexperienceswithedoxabanforstrokepreventioninatrialfibrillationinthesoutheastasiaregion AT mehtaradhika earlyexperienceswithedoxabanforstrokepreventioninatrialfibrillationinthesoutheastasiaregion |